Company intelligence / Profile preview

Doasense

Heidelberg, Baden-Württemberg, Germanydoasense.de ↗

Ownership: Private
Development stage: Other

Overview

The DOAC Dipstick has demonstrated good correlation with plasma levels of direct oral anticoagulants in clinical studies. It provides results within approximately ten minutes from urine collection and has been shown to be non-inferior or superior to standard laboratory methods for detecting factor Xa and thrombin inhibitors. The test has received IVDR certification in the EU and inclusion in several clinical guidelines as a rapid point-of-care solution for urgent decision-making scenarios such as stroke or emergency surgery.

Therapeutic areas: HematologyCardiovascularOther
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

Not explicitly listed; advisors have backgrounds with companies like bioMérieux and Haemonetics

Beyond the preview

Go deeper on Doasense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Doasense.

Explore the full profile